Literature DB >> 22392459

The CHADS₂versus the new CHA2DS2-VASc scoring systems for guiding antithrombotic treatment of patients with atrial fibrillation: review of the literature and recommendations for use.

Lauren E Odum1, Kelly A Cochran, Daniel S Aistrope, Kathleen A Snella.   

Abstract

The association of atrial fibrillation and resultant thromboembolic stroke is readily recognized in the published literature. However, the identification and weight of other risk factors that increase stroke risk are varied. To predict which patients are at greatest risk for thromboembolic stroke, numerous risk stratification schemas have been developed to guide thromboprophylactic treatment decisions. The well-known CHADS(2) scoring system incorporates risk factors such as congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, and previous stroke or transient ischemic attack. Recently, a novel risk stratification model, CHA2DS2 -VASc, has entered the literature and international guidelines, prompting further review of newly added risk factors-age 65-74 years, presence of vascular disease, and female sex-and the increased allotment of 2 points (vs 1 point in CHADS2) for age 75 years or older. The rationale for CHA2DS2 -VASc, as put forth by its authors, is that other risk assessment models omit important risk factors, have low predictive ability, and categorize too many patients as intermediate risk, leaving the choice of anticoagulant or antiplatelet therapy to the discretion of the clinician. Although CHA2DS2 -VASc readily identifies those patients truly at low risk, it classifies more patients as high risk who would then receive anticoagulation therapy. Therefore, implementation of this risk schema warrants further evaluation, especially when weighing the risk for bleeding and the risk for stroke. This critical review provides practitioners with an understanding of the literature that prompted the inclusion of these new risk factors and increased point allocations, compares and contrasts the risk schemas, and reviews national and international guidelines, thereby equipping the health care provider with the knowledge to aid clinical decision-making.
© 2012 Pharmacotherapy Publications, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22392459     DOI: 10.1002/j.1875-9114.2012.01023.x

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  15 in total

Review 1.  Dabigatran and left atrial appendage thrombus.

Authors:  Alejandro Vidal; Gabriel Vanerio
Journal:  J Thromb Thrombolysis       Date:  2012-11       Impact factor: 2.300

2.  Inpatient Mortality Risk Scores and Postdischarge Events in Hospitalized Heart Failure Patients: A Community-Based Study.

Authors:  Sithu Win; Imad Hussain; Virginia B Hebl; Shannon M Dunlay; Margaret M Redfield
Journal:  Circ Heart Fail       Date:  2017-07       Impact factor: 8.790

3.  Net Clinical Benefits of Guidelines and Decision Tool Recommendations for Oral Anticoagulant Use among Patients with Atrial Fibrillation.

Authors:  Anand R Shewale; Jill T Johnson; Chenghui Li; David Nelsen; Bradley C Martin
Journal:  J Stroke Cerebrovasc Dis       Date:  2015-10-21       Impact factor: 2.136

4.  Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System.

Authors:  Joshua Buck; Peter Kaboli; Brian F Gage; Peter Cram; Mary S Vaughan Sarrazin
Journal:  Am Heart J       Date:  2016-06-21       Impact factor: 4.749

5.  Association between risk of obstructive sleep apnea and cognitive performance, frailty, and quality of life among older adults with atrial fibrillation.

Authors:  Jordy Mehawej; Jane S Saczynski; Catarina I Kiefe; Hawa O Abu; Mayra Tisminetzky; Weijia Wang; Benita A Bamgbade; Eric Ding; Darleen Lessard; Edith Mensah Otabil; Connor Saleeba; Robert J Goldberg; David D McManus
Journal:  J Clin Sleep Med       Date:  2022-02-01       Impact factor: 4.324

6.  Online health information seeking, low atrial fibrillation-related quality of life, and high perceived efficacy in patient-physician interactions in older adults with atrial fibrillation.

Authors:  Jordy Mehawej; Ajay Mishra; Jane S Saczynski; Molly E Waring; Darleen Lessard; Hawa O Abu; Vincent La; Mayra Tisminetzky; Khanh-Van Tran; Essa Hariri; Andreas Filippaios; Tenes Paul; Apurv Soni; Weijia Wang; Eric Y Ding; Benita A Bamgbade; Joanne Mathew; Catarina Kiefe; Robert J Goldberg; David D McManus
Journal:  Cardiovasc Digit Health J       Date:  2022-03-11

7.  Adherence to treatment guidelines: the association between stroke risk stratified comparing CHADS2 and CHA2DS2-VASc score levels and warfarin prescription for adult patients with atrial fibrillation.

Authors:  Scott A Chapman; Catherine A St Hill; Meg M Little; Michael T Swanoski; Shellina R Scheiner; Kenric B Ware; M Nawal Lutfiyya
Journal:  BMC Health Serv Res       Date:  2017-02-11       Impact factor: 2.655

Review 8.  Atrial Fibrillation Genetics: Is There a Practical Clinical Value Now or in the Future?

Authors:  William J Hucker; Harsimran Saini; Steven A Lubitz; Patrick T Ellinor
Journal:  Can J Cardiol       Date:  2016-02-12       Impact factor: 5.223

9.  Stroke Prevention in Atrial Fibrillation - Outcomes and Future Directions.

Authors:  Katrina Mountfort; John Camm; Gregory Lip; Andreas Goette; Jean-Yves Le Heuzey
Journal:  Arrhythm Electrophysiol Rev       Date:  2014-11-29

10.  Factors Associated with Moderate Physical Activity Among Older Adults with Atrial Fibrillation.

Authors:  Jordy Mehawej; Jane S Saczysnki; Catarina I Kiefe; Eric Ding; Hawa O Abu; Darleen Lessard; Robert H Helm; Benita A Bamgbade; Connor Saleeba; Weijia Wang; David D McManus; Robert J Goldberg
Journal:  J Atr Fibrillation       Date:  2021-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.